LONDON (Reuters) – Britain’s AstraZeneca Plc (AZN.L) has approached U.S. rival Gilead Sciences Inc (GILD.O) about a possible merger that would form one the world’s largest drug companies, Bloomberg News reported on Sunday, citing people familiar with the matter.
FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo
Any deal would unite two of the companies at the forefront of the industry’s efforts to fight the new coronavirus and could be politically sensitive as governments seek control over potential vaccines or treatments.
AstraZeneca contacted Gilead last month, but the U.S. firm was not interested in combining with another big pharmaceutical company, the Bloomberg report bloom.bg/3h2GU9e…
Source news reuters.com, click here to read the full news.
